잠시만 기다려 주세요. 로딩중입니다.

Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model

Endocrinology and Metabolism 2021년 36권 1호 p.157 ~ 170
김진희, Lee Gha-Young, Maeng Hyo-Jin, 김호연, 배재현, 김경민, 임수,
소속 상세정보
김진희 ( Kim Jin-Hee ) - Seoul National University College of Medicine Seoul National University Bundang Hospital Department of Internal Medicine
 ( Lee Gha-Young ) - Seoul National University College of Medicine Seoul National University Bundang Hospital Department of Internal Medicine
 ( Maeng Hyo-Jin ) - Seoul National University College of Medicine Seoul National University Bundang Hospital Department of Internal Medicine
김호연 ( Kim Ho-Youn ) - Seoul National University College of Medicine Seoul National University Bundang Hospital Department of Internal Medicine
배재현 ( Bae Jae-Hyun ) - Korea University College of Medicine Korea University Anam Hospital Department of Internal Medicine
김경민 ( Kim Kyoung-Min ) - Seoul National University College of Medicine Seoul National University Bundang Hospital Department of Internal Medicine
임수 ( Lim Soo ) - Seoul National University College of Medicine Seoul National University Bundang Hospital Department of Internal Medicine

Abstract


Background: Glucagon-like peptide-1 (GLP-1) analogues regulate glucose homeostasis and have anti-inflammatory properties, but cause gastrointestinal side effects. The fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism that has poor pharmacokinetic properties, including a short half-life. To overcome these limitations, we investigated the effect of a low-dose combination of a GLP-1 analogue and FGF21 on atherosclerosis-related molecular pathways.

Methods: C57BL/6J mice were fed a high-fat diet for 30 weeks followed by an atherogenic diet for 10 weeks and were divided into four groups: control (saline), liraglutide (0.3 mg/kg/day), FGF21 (5 mg/kg/day), and low-dose combination treatment with liraglutide (0.1 mg/kg/day) and FGF21 (2.5 mg/kg/day) (n=6/group) for 6 weeks. The effects of each treatment on various atherogenesis-related pathways were assessed.

Results: Liraglutide, FGF21, and their low-dose combination significantly reduced atheromatous plaque in aorta, decreased weight, glucose, and leptin levels, and increased adiponectin levels. The combination treatment upregulated the hepatic uncoupling protein-1 (UCP1) and Akt1 mRNAs compared with controls. Matric mentalloproteinase-9 (MMP-9), monocyte chemoattractant protein-1 (MCP-1), and intercellular adhesion molecule-1 (ICAM-1) were downregulated and phosphorylated Akt (p-Akt) and phosphorylated extracellular signal-regulated kinase (p-ERK) were upregulated in liver of the liraglutide-alone and combination-treatment groups. The combination therapy also significantly decreased the proliferation of vascular smooth muscle cells. Caspase-3 was increased, whereas MMP-9, ICAM-1, p-Akt, and p-ERK1/2 were downregulated in the liraglutide-alone and combination-treatment groups

Conclusion: Administration of a low-dose GLP-1 analogue and FGF21 combination exerts beneficial effects on critical pathways related to atherosclerosis, suggesting the synergism of the two compounds.

키워드

Glucagon-like peptide 1; Fibroblast growth factor 21; Atherosclerosis; Diabetes mellitus; Inflammation

원문 및 링크아웃 정보

등재저널 정보